Hikma Pharmaceuticals PLC (STU:H5P)
€ 19.83 +1.58 (+8.66%) Market Cap: 4.14 Bil Enterprise Value: 5.59 Bil PE Ratio: 12.89 PB Ratio: 1.89 GF Score: 84/100

Half Year 2026 Hikma Pharmaceuticals PLC Earnings Call Transcript

Aug 06, 2026 / 08:30AM GMT
Release Date Price: €19.83 (+8.66%)
Said Darwazah
Hikma Pharmaceuticals PLC - Chief Executive Officer, Executive Director

Good morning, everyone, and thank you for joining us to discuss our results for the first half of '26. Today, I am pleased to report that our first half performance was in line with our expectations and demonstrates that we are delivering against the commitments we have made.

Over the last six months, the management team has spent considerable time meeting colleagues across our sites globally. What we have seen is a business with tremendous talent and growing momentum.

Through the actions we are taking, we are returning to being a more agile organization with faster decision making, clearer accountability, and greater empowerment, helping us make good progress against our strategic priorities while maintaining the stability and resilience that underpin the business. There are five key messages I would like you to take away from today's results.

First, we have delivered strong financial results in line with the expectations.

Second, we have delivered these results while increasing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot